The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease ...
The "Chronic Urticaria: Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.This report provides a data-driven overview of the current and future competitive landscape in ...
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD). The ...
Results that may be inaccessible to you are currently showing.